Amrinone
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| |
| Amrinone
| |
| Systematic (IUPAC) name | |
| 5-amino-3,4'-bipyridin-6(1H)-one | |
| Identifiers | |
| CAS number | |
| ATC code | C01 |
| PubChem | |
| Chemical data | |
| Formula | C10H9N3O |
| Mol. mass | 187.198 g/mol |
| Pharmacokinetic data | |
| Bioavailability | n/a |
| Protein binding | 10 to 49% |
| Metabolism | Hepatic |
| Half life | 5 to 8 hours |
| Excretion | Renal (63%) and fecal (18%) |
| Therapeutic considerations | |
| Pregnancy cat. |
C(US) |
| Legal status | |
| Routes | Intravenous |
|
WikiDoc Resources for Amrinone | |
|
Articles | |
|---|---|
|
Most recent articles on Amrinone | |
|
Media | |
|
Evidence Based Medicine | |
|
Clinical Trials | |
|
Ongoing Trials on Amrinone at Clinical Trials.gov Clinical Trials on Amrinone at Google
| |
|
Guidelines / Policies / Govt | |
|
US National Guidelines Clearinghouse on Amrinone
| |
|
Books | |
|
News | |
|
Commentary | |
|
Definitions | |
|
Patient Resources / Community | |
|
Directions to Hospitals Treating Amrinone Risk calculators and risk factors for Amrinone
| |
|
Healthcare Provider Resources | |
|
Causes & Risk Factors for Amrinone | |
|
Continuing Medical Education (CME) | |
|
International | |
|
| |
|
Business | |
|
Experimental / Informatics | |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Phone:617-632-7753
Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Overview
Amrinone (INN) or inamrinone, trade name Inocor, is a type 3 pyridine phosphodiesterase inhibitor. It is used in the treatment of congestive heart failure.
Class: Cardiac inotrope.
Actions: Increases cardiac contractility, vasodilator.
Indications: Short-term management of severe CHF.
Contraindications: Patients with history of hypersensitivity to the drug.
Precautions: May increase myocardial ischemia. Blood pressure, pulse, and EKG should be constantly monitored. Amrinone should only be diluted with normal saline or 1/2 normal saline; no dextrose solutions should be used. Furosemide should not be administered into an IV line delivering Amrinone.
Side Effects: Reduction in platelets, nausea and vomiting cardiac arrhythmias.
Dosage: 0.75 mg/kg bolus given slowly over 2-3 minute interval followed by maintenance infusion of 2-15 µg/kg/minute.
Routes: IV bolus and infusion as described earlier.
Pediatric Dosage: Safety in children has not been established
Selective Phosphodiesterase inhibitors (C01CE, G04BE) | |
|---|---|
| PDE1 | Vinpocetine |
| PDE2 | EHNA |
| PDE3 | Amrinone, Bucladesine, Enoximone, Milrinone |
| PDE4 | Etazolate, HT-0712, Ibudilast, Mesembrine, Rolipram |
| PDE5 | Avanafil, Sildenafil, Tadalafil, Udenafil, Vardenafil |
Cardiac stimulants excluding cardiac glycosides (C01C) | |
|---|---|
| Adrenergic and dopaminergic agents | Etilefrine • Isoprenaline • Norepinephrine • Dopamine • Norfenefrine • Phenylephrine • Dobutamine • Oxedrine • Metaraminol • Methoxamine • Mephentermine • Dimetofrine • Prenalterol • Dopexamine • Gepefrine • Ibopamine • Midodrine • Octopamine • Fenoldopam • Cafedrine • Arbutamine • Theodrenaline • Epinephrine |
| Phosphodiesterase inhibitors (PDE3I) | Amrinone • Milrinone • Enoximone • Bucladesine |
| Other cardiac stimulants | Angiotensinamide • Xamoterol • Levosimendan |
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
